Loading clinical trials...
Loading clinical trials...
A Randomized, Double-Blind, Placebo Controlled, Cross-Over Study to Evaluate the Efficacy, Safety and Tolerability of Daily Oral SCI-110 in Treating Adults With Tourette Syndrome.
Conditions
Interventions
SCI-110
Placebo
Locations
3
United States
Yale Child Study Center - NIHB 205
New Haven, Connecticut, United States
Medizinische Hochschule Hannover
Hanover, Germany
Neurological Institute, Tel Aviv Sourasky Medical Center
Tel Aviv, Israel
Start Date
August 1, 2025
Primary Completion Date
October 1, 2025
Completion Date
February 1, 2026
Last Updated
May 16, 2025
NCT06678737
NCT03851484
NCT04449068
NCT05558566
NCT06194305
NCT06873841
Lead Sponsor
Neurothera Labs Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions